Skip to content
10-Q

Quarterly Report

Atrium Therapeutics, Inc. RNA

0001193125-26-224243

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 17.11M sh
Shares Diluted Q1 2026 · Mar 31, 2026 17.11M sh
Shares Diluted Q1 2026 · Mar 31, 2025 17.11M sh
Capex Q1 2026 · Mar 31, 2026 $2.1M
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$31.14M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$11.1M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $267.85M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $0
Cash And Equivalents Q1 2026 · Mar 31, 2025 $0
Stockholders Equity Q1 2026 · Mar 31, 2026 $234.1M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$62.71M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$56.3M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$61.11M
Current Liabilities Q1 2026 · Mar 31, 2026 $21.91M
Current Liabilities Q1 2026 · Dec 31, 2025 $41.8M
Total Liabilities Q1 2026 · Mar 31, 2026 $58.26M
Total Liabilities Q1 2026 · Dec 31, 2025 $71.07M
Current Assets Q1 2026 · Mar 31, 2026 $285.57M
Current Assets Q1 2026 · Dec 31, 2025 $2.85M
Total Assets Q1 2026 · Mar 31, 2026 $292.36M
Total Assets Q1 2026 · Dec 31, 2025 $8.35M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.97
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.44
Eps Basic Q1 2026 · Mar 31, 2026 −$0.97
Eps Basic Q1 2026 · Mar 31, 2025 −$0.44
Sga Expense Q1 2026 · Mar 31, 2026 $20.26M
Sga Expense Q1 2026 · Mar 31, 2025 $2.09M
Rd Expense Q1 2026 · Mar 31, 2026 $16.66M
Rd Expense Q1 2026 · Mar 31, 2025 $6.94M
Net Income Q1 2026 · Mar 31, 2026 −$16.63M
Net Income Q1 2026 · Mar 31, 2025 −$7.45M
Operating Income Q1 2026 · Mar 31, 2026 −$17.28M
Operating Income Q1 2026 · Mar 31, 2025 −$7.45M
Revenue Q1 2026 · Mar 31, 2026 $19.64M
Revenue Q1 2026 · Mar 31, 2025 $1.57M